Analogs of glucagon exhibiting GIP receptor activity
Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
1. A glucagon analog exhibiting glucagon, GLP-1 and GIP receptor activity, said analog consisting of the sequence of SEQ ID NO: 12.
2. A pharmaceutical composition comprising the glucagon analog of claim 1 and a pharmaceutically acceptable carrier.
3. A glucagon analog exhibiting glucagon, GLP-1 and GIP receptor activity, said analog selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 143 and SEQ ID NO: 146.